1. 1319 A prevalence study of drug-drug interactions in metastatic prostate cancer patients receiving abiraterone. (September 2015) Authors: Bonnet, C.; Thomas-Schoemann, A.; Boudou-Rouquette, P.; Huillard, O.; Carton, E.; Cessot, A.; Morin, B.; Giroux, J.; Tlemsani, C.; Arrondeau, J.; Vidal, M.; Blanchet, B.; Alexandre, J.; Goldwasser, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S193 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2547 Low abiraterone plasma concentration fails to induce PSA regression in metastatic castration-resistant prostate cancer patients. (September 2015) Authors: Carton, E.; Noe, G.; Huillard, O.; Golmard, J.L.; Giroux, J.; Cessot, A.; Peyromaure, M.; Zerbib, M.; Narjoz, C.; Thomas, A.; Vidal, M.; Goldwasser, F.; Blanchet, B.; Alexandre, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S491 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3451 Insulin-resistance in sarcoma patients: analysis of a prospective cohort. (September 2015) Authors: Tlemsani, C.; Huillard, O.; Boudou-Rouquette, P.; Arrondeau, J.; Cessot, A.; Jouinot, A.; Durand, J.P.; Alexandre, J.; Anract, P.; Goldwasser, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 371 Potential benefit of pharmacokinetically-guided dosing strategy for the decision making in cancer patients treated with sunitinib. (September 2015) Authors: Cabel, L.; Blanchet, B.; Alexandre, J.; Huillard, O.; Coriat, R.; Cessot, A.; Giroux, J.; Thomas, A.; Vidal, M.; Goldwasser, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours. Issue 6 (30th January 2019) Authors: Cohen, R.; Preta, L. H.; Joste, V.; Curis, E.; Huillard, O.; Jouinot, A.; Narjoz, C.; Thomas‐Schoemann, A.; Bellesoeur, A.; Tiako Meyo, M.; Quilichini, J.; Desaulle, D.; Nicolis, I.; Cessot, A.; Vidal, M.; Goldwasser, F.; Alexandre, J.; Blanchet, B. Journal: British journal of clinical pharmacology Issue: Volume 85:Issue 6(2019) Page Start: 1227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. (February 2017) Authors: Carton, E.; Noe, G.; Huillard, O.; Golmard, L.; Giroux, J.; Cessot, A.; Saidu, N.E.B.; Peyromaure, M.; Zerbib, M.; Narjoz, C.; Guibourdenche, J.; Thomas, A.; Vidal, M.; Goldwasser, F.; Blanchet, B.; Alexandre, J. Journal: European journal of cancer Issue: Volume 72(2017) Page Start: 54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗